Table 3 |
||||||||||||||||
|
Effect Sizes for all measures in all studies examined. |
||||||||||||||||
| First Author (reference) |
N |
Design |
Recording Time |
Drug |
Treatment Period (Weeks) |
*CB |
Effect Size (Cohen's d) |
|||||||||
| HR |
SDNN |
SDANN |
RMSSD |
LF |
ln HF |
HF |
LF/HF |
CV |
pNN50 |
|||||||
|
|
||||||||||||||||
| TCAs Short time recording |
||||||||||||||||
| Rechlin[55] |
24 |
pre post |
5 min |
amitriptyline |
2 |
Y |
4.43 |
-1.61 |
-2.97 |
-0.87 |
-9.44 |
|||||
| Rechlin [56] |
24 |
pre post |
5 min |
amitriptyline |
2 |
Y |
5.52 |
-2.59 |
-2.93 |
-1.19 |
-8.85 |
|||||
| Rechlin [57] |
104 |
drug vs control |
5 min |
amitriptyline |
1 |
Y |
1.60 |
-1.53 |
-1.87 |
-0.54 |
-4.76 |
|||||
| Rechlin [58] |
26 |
drug vs control |
5 min |
amitriptyline |
2 |
Y |
3.81 |
-2.55 |
-3.58 |
-1.25 |
-3.97 |
|||||
| Rechlin [59] |
8 |
pre post |
5 min |
amitriptyline |
2 |
Y |
6.11 |
-1.88 |
-3.66 |
-10.86 |
||||||
| Rechlin [59] |
8 |
pre post |
5 min |
doxepin |
2 |
Y |
7.87 |
-3.51 |
-5.04 |
-21.44 |
||||||
| Tulen[9] |
9 |
pre post |
8 min |
imipramine |
4 |
Y |
4.81 |
-2.44 |
-6.43 |
-3.97 |
||||||
| Volkers[60] |
24 |
pre post |
5 min |
imipramine |
4 |
Y |
4.52 |
-3.32 |
-2.64 |
-5.52 |
||||||
| TCAs Long time recording |
||||||||||||||||
| Khaykin[51] |
9 |
pre post |
24 h |
doxepin |
6 |
N |
1.80 |
3.64 |
-2.71 |
-3.34 |
||||||
| Lederbogen[50] |
14 |
pre post |
24 h |
amitriptyline |
5 |
N |
1.98 |
-2.20 |
-3.01 |
|||||||
| SSRIs Short time recording |
||||||||||||||||
| Rechlin [56] |
24 |
pre post |
5 min |
paroxetine |
2 |
Y |
-0.45 |
0.05 |
-0.61 |
-0.30 |
-0.09 |
|||||
| Rechlin [59] |
8 |
pre post |
5 min |
fluvoxamine |
2 |
Y |
-0.83 |
0.03 |
1.47 |
-0.42 |
||||||
| Rechlin [59] |
8 |
pre post |
5 min |
paroxetine |
2 |
Y |
-0.77 |
0.09 |
-0.39 |
-0.27 |
||||||
| Straneva-Meuse[61] |
17 |
vs control |
2 min |
paroxetine |
8 |
N |
-1.99 |
|||||||||
| Volkers[60] |
17 |
pre post |
5 min |
fluvoxamine |
4 |
Y |
-0.47 |
-0.15 |
||||||||
| SSRIs Long time recording |
||||||||||||||||
| Khaykin[51] |
5 |
pre post |
24 h |
fluoxetine |
6 |
N |
2.24 |
2.81 |
1.76 |
1.76 |
||||||
| Lederbogen[50] |
14 |
pre post |
24 h |
paroxetine |
5 |
N |
-0.10 |
-1.21 |
-1.95 |
|||||||
| Other Treatments |
||||||||||||||||
| Agelink[62] |
25 |
pre-post |
5 min |
reboxetine |
3 |
Y |
1.32 |
-0.04 |
-0.38 |
0.79 |
||||||
| Agelink[63] |
25 |
pre-post |
5 min |
nefazodone |
3 |
Y |
-1.60 |
0.08 |
0.11 |
-0.08 |
-0.20 |
-0.16 |
-0.21 |
|||
| Straneva-Meuse[61] |
17 |
vs control |
2 min |
bupropion |
8 |
N |
-1.99 |
|||||||||
| Tulen[9] |
8 |
pre post |
8 min |
mirtazapine |
4 |
Y |
4.81 |
-2.44 |
-1.81 |
-3.97 |
||||||
| Karpyak[52] |
11 |
pre post |
24 h |
ECT |
** |
NS |
0.51 |
0.90 |
||||||||
| Nahshoni[53] |
10 |
pre-post |
NS |
ECT |
*** |
NS |
-0.88 |
0.84 |
||||||||
|
HR = heart rate. CV = coefficient of variability. NS = Not Stated. *CB = Controlled Breathing;. **ECT performed 3 times per week to a maximum of 10 treatments. ***ECT performed 2 times per week to a maximum of 12 treatments. | ||||||||||||||||
van Zyl et al. BioPsychoSocial Medicine 2008 2:12 doi:10.1186/1751-0759-2-12 |
||||||||||||||||